TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development - Test2 - elhamkhani - TriplyDB

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

http://www.wikidata.org/entity/Q36249542

about

Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling Bone specific immunity and its impact on metastasis Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.Interaction of dietary fatty acids with tumour necrosis factor family cytokines during colon inflammation and cancer.Fucosylation is a promising target for cancer diagnosis and therapy Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.Airway Inflammation after Bronchial Thermoplasty for Severe Asthma.TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impact Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis Death receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout.Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.Integrative genomics in combination with RNA interference identifies prognostic and functionally relevant gene targets for oral squamous cell carcinoma.Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.Understanding the Role of the Death Receptor 5/FADD/caspase-8 Death Signaling in Cancer Metastasis Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis.A homeostatic switch in PACS-2 links membrane traffic to TRAIL-induced apoptosis.A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Apoptosis, autophagy, necroptosis, and cancer metastasis Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.Control of FLIP(L) expression and TRAIL resistance by the extracellular signal-regulated kinase1/2 pathway in breast epithelial cells.Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis.Life and death by death receptors.Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans?The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.Following TRAIL's path in the immune system.Immune Regulation of the Metastatic Process: Implications for Therapy.TRAIL receptor signaling and therapeutics.Fucosylation and gastrointestinal cancer.Targeting the extrinsic apoptosis signaling pathway for cancer therapy.The therapeutic potential of TRAIL receptor signalling in cancer cells.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium.

P2860

Q24296451-1134EDE9-C779-4ECD-8FED-DF0E1AB6E88F Q27022883-C5153888-C036-48E3-AA79-AE1F864D3BD0 Q30541198-8396C64A-4ECC-402A-95E4-EABDE533A889 Q33523025-C25A643E-0E5E-4970-8473-7F193002D4C2 Q33614335-45022EBA-B4CE-439E-A9FC-8476B7C64AE0 Q33649601-A3A07BCA-4365-42DF-A24F-D0CA9FA8081B Q33723716-BCFCCF42-997B-4661-B152-6440C815E603 Q33786116-9169F760-F808-4067-9312-416508D802BF Q33802751-BD8845A8-2EDB-4B64-9D57-74281A9A6E6E Q34028464-1C38401B-0660-49BD-B9EE-FD6812C6E3D2 Q34068822-CA9BE48B-46EA-4ABB-A77B-42B4D3D19D96 Q34145860-E9C7B1B9-AAB0-4188-AF3F-A8D252BC6CCA Q34413462-F259B28E-5B25-4458-A1EC-9D98DC1D8379 Q34464915-656C256D-006B-4BF5-A9C3-47ED80E61807 Q34532108-E69B0616-490E-492E-90FF-9C2A4697449E Q34558023-C2DF2F87-E14B-4E48-A8BC-72E0F7DC8F17 Q34608366-C60AAD27-CF49-4D2A-89EB-0563AFE6A85B Q34731599-6959CBD3-78D7-4A75-81C5-301757D3130D Q34809370-5A736F87-3E6B-4A2D-B687-6B7A7ACC2E24 Q34989102-93C26603-D8F6-403E-9191-2CE4B1AE7E64 Q35038107-5BB1F870-D41D-409B-9566-B5DD25E2F3FF Q35128650-8E12C238-909D-4569-BEB5-CDDD712F52D2 Q35480734-F1299B52-CB6A-4210-A132-70C92A5A0143 Q35931441-925D739F-DA75-47A5-BA5B-A42BF452FF1A Q36418691-707259C0-C263-45CC-B805-902E91468A61 Q36562365-8613574C-4C42-4103-A81F-A7E859611730 Q36731174-9C4013CC-D6B8-44C2-BFAF-070084B902B9 Q37071019-805BE234-BA6E-4618-B170-24E5577F2778 Q37122404-018A152F-8809-4D47-97D8-B8B22DCBD50F Q37233180-59E4D9C6-E380-4201-BF04-8774988DB434 Q37234170-CA21152D-3760-4EA5-8FED-3FD0DFFAB811 Q37302737-6ED467EA-02C6-4C45-A27A-61810C765A83 Q37498946-38B92933-93F1-4984-9628-8A19E60D2D38 Q37719488-19DEE65E-12C7-41DB-BB39-375DDB5B808E Q37785559-4E08A8F9-1422-4A69-900B-BAA323D6AAD7 Q37821306-5AF866EE-1D1E-48F1-8640-E9F17CD80287 Q37882480-466A7BBA-FBFE-49DF-88E1-C3D462238925 Q37962655-AB510A2B-D4EE-4306-A4D5-29D13812AD9A Q37972139-F174AACC-60E3-4095-B21A-203CAB511676 Q37992502-7095D616-C1B8-4F41-9022-C748618AB853

P2860

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

http://www.wikidata.org/entity/Q36249542

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

TRAIL-R deficiency in mice enh ...... ting primary tumor development

@ast

TRAIL-R deficiency in mice enh ...... ting primary tumor development

@en

type

label

TRAIL-R deficiency in mice enh ...... ting primary tumor development

@ast

TRAIL-R deficiency in mice enh ...... ting primary tumor development

@en

prefLabel

TRAIL-R deficiency in mice enh ...... ting primary tumor development

@ast

TRAIL-R deficiency in mice enh ...... ting primary tumor development

@en

P1433

Q36249542-244F71C3-3A9B-42CE-BEFF-C30EFFF1B629

P1476

Q36249542-1B2CE9DB-3166-478F-929C-476FEDB2ABCE

P2093

Q36249542-041FA3EB-5D20-43AA-8260-D1F494976D38

Q36249542-271E95B3-8EC1-4F9A-8668-AB64D04F4FDA

Q36249542-3B1712E9-1FD3-4CAC-8AB5-765821B78D50

Q36249542-63AE5780-48CE-44BD-9926-AA85AF0931D1

Q36249542-683A48EE-B6D9-4DCD-B0B3-50499D07321B

Q36249542-83A298C8-5F8A-4E0A-AF31-A6A5B091929F

Q36249542-9331DE60-FF4A-4A4C-8BD3-2C1E9E415898

Q36249542-C82C63B8-0D12-457C-879B-AAFEEDD73960

Q36249542-D2B77AB4-CF7C-42FF-ADAC-7AA9B24E954A

Q36249542-FF86BCA9-81EF-44B0-A628-5C6539B155EB

P2860

Q36249542-042CF900-E1DB-4B91-AE23-63FF6C9DD926

Q36249542-04D0C083-0233-4912-B9F8-B6964AF1D136

Q36249542-0781DC42-75FC-47B2-B879-E10A1CF63D33

Q36249542-10ABF3E4-F37C-4C11-9BF2-0A37C64AEE81

Q36249542-1581F762-289F-41CF-8E00-A34852616D8D

Q36249542-21CB4C27-D16E-4B17-B7B7-EE5FB17604DF

Q36249542-267918AF-57C5-4C6A-96C9-FF0584A3D271

Q36249542-2C5340A9-3E0D-4BAF-B092-5EDEC7F7EB67

Q36249542-2E434A5D-DCF2-4F11-9F90-DA9012A23E75

Q36249542-2F6074FD-17B9-4060-BFF0-C644C1533F7F

P304

Q36249542-373A9701-FB1A-4EC7-ACEF-ED806A657376

P31

Q36249542-749957E8-2914-44D7-AFB9-B47C2EDA3EC0

P356

Q36249542-032B3D92-7680-4C97-B9AA-75D2A77CB1FC

P407

Q36249542-2A82CB00-1CD9-42DE-B597-161936F4EACC

P433

Q36249542-08B6E60E-A4CF-415B-A74B-0E2D1A6A37E1

P478

Q36249542-2C396527-7103-483A-9365-6AB8708BBACC

P577

Q36249542-2C3C3ADA-8360-4354-A93B-3D97396064AD

P5875

Q36249542-B7045ACF-5C17-4848-AA4F-CE4EE4DEE9CE

P698

Q36249542-FA0073D1-BBF2-45A9-90F1-1A4048B7E509

P921

Q36249542-5DFB1FBB-9B4C-4550-94C8-17A3438250B8

P932

Q36249542-EF5BB20A-748D-4F54-8C7E-A6B7B399DC99

P356

P1433

Journal of Clinical Investigation

P1476

TRAIL-R deficiency in mice enh ...... ting primary tumor development

@en

P2093

Andreea I Csernok

http://www.w3.org/2001/XMLSchema#string

Anne Grosse-Wilde

http://www.w3.org/2001/XMLSchema#string

Christopher J Kemp

http://www.w3.org/2001/XMLSchema#string

Erich F Greiner

http://www.w3.org/2001/XMLSchema#string

Gary M Longton

http://www.w3.org/2001/XMLSchema#string

Günther Schütz

http://www.w3.org/2001/XMLSchema#string

Henning Walczak

http://www.w3.org/2001/XMLSchema#string

Oksana Voloshanenko

http://www.w3.org/2001/XMLSchema#string

S Lawrence Bailey

http://www.w3.org/2001/XMLSchema#string

Uta Schaefer

http://www.w3.org/2001/XMLSchema#string

P2860

p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways

Metastasis: a question of life or death

Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Longitudinal data analysis for discrete and continuous outcomes

Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application

Safety and antitumor activity of recombinant soluble Apo2 ligand.

DR5 knockout mice are compromised in radiation-induced apoptosis

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.

T cells require TRAIL for optimal graft-versus-tumor activity.

Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis.

P304

100-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI33061

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5768558

http://www.w3.org/2001/XMLSchema#string

P698

18079967

http://www.w3.org/2001/XMLSchema#string

P921

P932

2129237

http://www.w3.org/2001/XMLSchema#string